Literature DB >> 12411451

Angiotensin blockade prevents type 2 diabetes by formation of fat cells.

Arya M Sharma1, Jürgen Janke, Kerstin Gorzelniak, Stefan Engeli, Friedrich C Luft.   

Abstract

Obesity is the prime risk factor for the development of type 2 diabetes. Recent clinical trials have shown that blockade of the renin-angiotensin system, either by inhibiting the angiotensin-converting enzyme or blocking the angiotensin type 1 receptor, may substantially lower the risk for type 2 diabetes. The mechanism underlying this effect is unknown. Based on our recent observation that angiotensin II markedly inhibits adipogenic differentiation of human adipocytes via the angiotensin type I receptor and that expression of angiotensin II-forming enzymes in adipose tissue is inversely correlated with insulin sensitivity, we propose the hypothesis that blockade of the renin-angiotensin system prevents diabetes by promoting the recruitment and differentiation of adipocytes. Increased formation of adipocytes would counteract the ectopic deposition of lipids in other tissues (muscle, liver, pancreas), thereby improving insulin sensitivity and preventing the development of type 2 diabetes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12411451     DOI: 10.1161/01.hyp.0000036448.44066.53

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  51 in total

Review 1.  Earlier management of subjects who are prone to hypertension and diabetes mellitus.

Authors:  Hiromi Rakugi; Toshio Ogihara
Journal:  Curr Diab Rep       Date:  2004-04       Impact factor: 4.810

2.  Effects of different types of antihypertensive agents on arterial stiffness: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Xiahuan Chen; Bo Huang; Meilin Liu; Xueying Li
Journal:  J Thorac Dis       Date:  2015-12       Impact factor: 2.895

Review 3.  Antihypertensive drugs and incidence of type 2 diabetes: evidence and implications for clinical practice.

Authors:  Samuel Asfaha; Raj Padwal
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

Review 4.  [Blood pressure independent effects of antihypertensive agents].

Authors:  U Wenzel; G Wolf
Journal:  Internist (Berl)       Date:  2005-05       Impact factor: 0.743

5.  Regulating adiponectin: of flax and flux.

Authors:  A M Sharma; M A Tarnopolsky
Journal:  Diabetologia       Date:  2005-06       Impact factor: 10.122

Review 6.  Metabolic actions of angiotensin receptor antagonists: PPAR-gamma agonist actions or a class effect?

Authors:  Paul Ernsberger; Richard J Koletsky
Journal:  Curr Opin Pharmacol       Date:  2007-02-15       Impact factor: 5.547

7.  The effects of irbesartan and telmisartan on metabolic parameters and blood pressure in obese, insulin resistant, hypertensive patients.

Authors:  R Negro; G Formoso; H Hassan
Journal:  J Endocrinol Invest       Date:  2006-12       Impact factor: 4.256

Review 8.  Antihypertensive treatment and new-onset diabetes mellitus.

Authors:  Tonje Amb Aksnes; Henrik M Reims; Sverre E Kjeldsen; Giuseppe Mancia
Journal:  Curr Hypertens Rep       Date:  2005-08       Impact factor: 5.369

Review 9.  Targeting hypertension in patients with cardiorenal metabolic syndrome.

Authors:  Edward Rojas; Manuel Velasco; Valmore Bermúdez; Zafar Israili; Peter Bolli
Journal:  Curr Hypertens Rep       Date:  2012-10       Impact factor: 5.369

10.  Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.

Authors:  H C Gerstein; S Yusuf; R Holman; J Bosch; J Pogue
Journal:  Diabetologia       Date:  2004-08-21       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.